9 research outputs found
An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors
BACKGROUND: BXQ-350 is a novel anti-neoplastic agent composed of saposin C (SapC) and phospholipid dioleoylphosphatidyl-serine sodium (DOPS) that selectively binds tumor cell phosphatidylserine (PS), inducing apoptosis. BXQ-350 has demonstrated preclinical antitumor effects in high-grade gliomas (HGG) and clinical activity in adult patients with recurrent HGG.
METHODS: A phase 1 study was conducted in pediatric patients with relapsed/refractory solid tumors, including recurrent brain tumors. Primary objectives were to characterize safety and determine maximum tolerated dose (MTD) and preliminary antitumor activity. Sequential dose cohorts were assessed up to 3.2 mg/kg using an accelerated titration design. Each cycle was 28 days; dosing occurred on days 1-5, 8, 10, 12, 15, and 22 of cycle 1, and day 1 of subsequent cycles, until disease progression or toxicity.
RESULTS: Nine patients, median age 10 years (range: 4-23), were enrolled. Seven patients (78%) had central nervous system (CNS) and two (22%) had non-CNS tumors. Eight patients completed cycle 1. No dose limiting toxicity (DLT) or BXQ-350-related serious adverse events (SAEs) were observed. Six patients experienced at least one adverse event (AE) considered possibly BXQ-350-related, most were grade â€2. One patient with diffuse intrinsic pontine glioma experienced stable disease for 5 cycles. The study was terminated after part 1 to focus development on the frontline setting.
CONCLUSION: No DLTs or BXQ-350-related SAEs were reported, and the maximal planned dose of 3.2 mg/kg IV was tolerable. Limited safety and efficacy data support continued BXQ-350 development in pediatric HGG; however, early discontinuations for progression suggest novel therapies be assessed at earlier disease stages
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049
FDA Drug Approval Summary: Alemtuzumab as SingleâAgent Treatment for BâCell Chronic Lymphocytic Leukemia
Labeling recommendations based on exposure-response relationships to minimize musculoskeletal related adverse reactions of a Hedgehog inhibitor.
U.S. Food and Drug Administration Approval: Peginterferonâalfaâ2b for the Adjuvant Treatment of Patients with Melanoma
Morphodynamics of Supercritical Turbidity Currents in the Channel-Lobe Transition Zone
This study aims to resolve process-facies links at both bed and environmental scales for the channel lobe transition zone (CLTZ). Data comes from existing experimental and modern CLTZ studies and from new outcrop studies. The experiments show that the CLTZ architecture of supercritical turbidity currents is complex and different from their counterparts where flows are subcritical throughout. Supercritical CLTZâs are characterised by erosive channels formed by supercritical turbidity currents, by offset stacked lobes deposited from subcritical turbidity currents and by hydraulic jump related mouth bar deposits and upslope onlapping backfill deposits at the down slope end of the transition zone. Erosive channels and backfill features can be resolved by high resolution seismic data, yet evidence for supercritical flow must come from facies analysis of core data. Outcrop examples of the CLTZ from the Tabernas submarine fan (SE Spain) and the Llorenç del Munt deep-water delta slope (N. Spain) are used to establish such links between seismic scale architecture and facies recognised in cores. The outcrops described here were mapped as transition zone, and show 100 m sized, spoon-shaped scours filled with sediment containing sandy to gravelly backsets up to 4 m in height. Their facies and architecture is indicative of deposition by hydraulic jumps, can be recognized from cores, and is a good proxy for further predicting CLTZ architecture constructed by supercritical turbidity currents